流体介导的DNA损伤促进了高等级的血清性卵巢癌的发病
bioRxiv : the preprint server for biology
|June 10, 2024
概括
经过表观遗传改变的介质干细胞 (hrMSCs) 驱动DNA损伤,并促进输卵管细胞的存活,启动高度血清性卵巢癌 (HGSOC). 这些hrMSC与BRCA1/2突变和衰老有关,这表明HGSOC检测和预防的新目标.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 遗传学 是一个遗传学.
背景情况:
- 高度血清性卵巢癌 (HGSOC) 的发病机制在很大程度上是未知的,这阻碍了有效的预防和早期检测策略.
- 大多数HGSOC病例被认为起源于输卵管表皮质 (FTE),目前的模型表明突变的逐步积累.
- 现有的模型无法完全解释明显癌变之前的早期细胞事件.
研究的目的:
- 调查表观遗传改变的介质干细胞 (hrMSCs) 在高度血清性卵巢癌 (HGSOC) 发病中的作用.
- 为了确定hrMSCs是否可以驱动正常输卵管上皮质 (FTE) 细胞的恶性转变.
- 在卵巢癌发病背景下,探索 hrMSC 与 BRCA1/2 突变和衰老的关联.
主要方法:
- 在癌前病变中检测和描述表观遗传改变的介质干细胞 (hrMSCs).
- 评估HRMSC诱导的DNA损伤 (DNA双链断裂) 和FTE细胞中的细胞存活率.
- 在体内研究,以评估hrMSCs诱导原发性FTE细胞恶性转化和转移的能力.
- 对BRCA1/2突变载体中hrMSC丰富的分析以及与年龄的相关性.
主要成果:
- 在卵巢癌前体病变形成之前,已经确定了表观遗传改变的介质干细胞 (hrMSCs).
- 发现hrMSCs可诱导FTE细胞中的DNA双链断裂,并在破坏DNA的条件下增强它们的存活率.
- hrMSCs证明了诱导初级FTE细胞恶性转化的能力,导致体内转移性癌症.
- hrMSCs在BRCA1/2突变载体中显著丰富,并且随着年龄的增长,患病率增加.
结论:
- 经过表观遗传改变的介质干细胞 (hrMSCs) 可能在诱导高度血清性卵巢癌 (HGSOC) 发病方面发挥关键作用.
- hrMSCs的存在,特别是在BRCA1/2突变和年龄较大的个体中,表明它们是卵巢癌发展的关键因素.
- 这些发现为卵巢癌的病原性提供了新的见解,并突出了早期检测和预防策略的潜在新途径.
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
Oogenesis
63.7K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.7K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


